Annals of Surgical Oncology

, Volume 7, Issue 1, pp 67–71 | Cite as

Surgical Oncology Forum: Tamoxifen for the Prevention of Breast Cancer in the High-Risk Woman

  • Monica Morrow
  • V. Craig Jordan
Surgical Oncology Forum


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–1388.CrossRefPubMedGoogle Scholar
  2. 2.
    Powles TJ, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98–101.PubMedGoogle Scholar
  3. 3.
    Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women: Italian Tamoxifen Prevention Study. Lancet 1998;352:93–97.PubMedGoogle Scholar
  4. 4.
    Lacassagne A. Hormonal pathogenesis of adenocarcinoma of the breast. Am J Cancer 1936;14:217–225.Google Scholar
  5. 5.
    Jensen EV, Jacobson HI. Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 1962;18:387–414.Google Scholar
  6. 6.
    Jensen EV, Block GE, Smith S, Kyser K, DeSombre ER. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr 1971;34:55–70.PubMedGoogle Scholar
  7. 7.
    Skidmore J, Walpole AL, Woodburn J. Effect of some triphenylethylenes on oestradiol binding in vitro to macromolecules from uterus and anterior pituitary. J Endocrinol 1972;52:289–298.CrossRefPubMedGoogle Scholar
  8. 8.
    Jordan VC, Koerner S. Tamoxifen (ICI 46474), and the human carcinoma 8S oestrogen receptor. Eur J Cancer 1975;11:205–206.PubMedGoogle Scholar
  9. 9.
    Jordan VC. Effect of tamoxifen (ICI 46474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 1976;12:419–424.PubMedGoogle Scholar
  10. 10.
    Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987;47:4020–4024.PubMedGoogle Scholar
  11. 11.
    Jordan VC, Lababidi MK, Langan-Fahey S. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst 1991;83:492–496.PubMedGoogle Scholar
  12. 12.
    Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet 1985;ii:282.Google Scholar
  13. 13.
    Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451–1467.Google Scholar
  14. 14.
    Terenius L. Structure-activity relationships of anti-oestrogens with regard to interaction with 17-beta-oestradiol in the mouse uterus and vagina. Acta Endocrinol (Copenh) 1971;66:431–437.Google Scholar
  15. 15.
    Jordan VC, Robinson SP. Species specific pharmacology of antiestrogens: role of metabolism. Fed Proc 1987;46:1870–1874.PubMedGoogle Scholar
  16. 16.
    Jordan VC, Phelps E, Lindgren JU. Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 1987;10:31–35.PubMedGoogle Scholar
  17. 17.
    Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting Contrasting trasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988;48:812–815.PubMedGoogle Scholar
  18. 18.
    Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852–856.PubMedCrossRefGoogle Scholar
  19. 19.
    Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991;115:860–864.PubMedGoogle Scholar
  20. 20.
    Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69:237–238.PubMedGoogle Scholar
  21. 21.
    Assikis VJ, Jordan VC. Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynaecol Obstet 1995;49:241–257.PubMedGoogle Scholar
  22. 22.
    Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879–1886.PubMedGoogle Scholar
  23. 23.
    Spiegelman D, Colditz GA, Hunter D, Hertzmark E. Validation of the Gail et al model for predicting individual breast cancer risk. J Natl Cancer Inst 1994;86:600–607.PubMedGoogle Scholar
  24. 24.
    Bondy ML, Lustbader ED, Halabi S, Ross E, Vogel VG. Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 1994;86:620–625.PubMedGoogle Scholar
  25. 25.
    Wickerham DL, Costantino J, Fisher B, Kavanah M, Wolmark N. Average annual rates of invasive and noninvasive breast cancer by history of LCIS and atypical hyperplasia for participants in the BCPN. Proc Am Soc Clin Oncol 99;18:87a.Google Scholar
  26. 26.
    Powles TJ, Hardy JR, Ashley SE, et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 1989;60:126–131.PubMedGoogle Scholar
  27. 27.
    Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res 1990;50:4177–4189.PubMedGoogle Scholar
  28. 28.
    Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641–1647.CrossRefPubMedGoogle Scholar
  29. 29.
    Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial: Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189–2197.CrossRefPubMedGoogle Scholar
  30. 30.
    Jordan VC, Morrow M. Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 1999;20:253–278.PubMedGoogle Scholar
  31. 31.
    Jordan VC. Estrogen receptor as a target for the prevention of breast cancer. J Lab Clin Med 1999;133:408–414.PubMedGoogle Scholar
  32. 32.
    MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998;50:151–196.PubMedGoogle Scholar
  33. 33.
    Jordan VC. Designer estrogens. Sci Am 1998;274:60–67.CrossRefGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2000

Authors and Affiliations

  • Monica Morrow
    • 1
  • V. Craig Jordan
    • 2
  1. 1.Lynn Sage Breast Program, Department of SurgeryNorthwestern University Medical SchoolChicago
  2. 2.Lynn Sage Breast Program, Robert H. Lurie Comprehensive Cancer CenterNorthwestern University Medical SchoolChicago

Personalised recommendations